Kiyoshi KikuchiHisaaki UchikadoNaoki MiuraYoko MorimotoTakashi ItoSalunya TancharoenKei MiyataRokudai SakamotoChiemi KikuchiNarumi IidaNaoto ShiomiTerukazu KuramotoNaohisa MiyagiKo Ichi KawaharaYame General HospitalKurume University School of MedicineKagoshima University Faculty of MedicineMahidol UniversityKagoshima UniversityNishida Koutoku HospitalKohjin Co., Ltd.Saiseikai Shiga HospitalOmuta City General HospitalOsaka Institute of Technology2018-05-032018-05-032011-09-01Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 767-77017921015179209812-s2.0-79960267925https://repository.li.mahidol.ac.th/handle/20.500.14594/11484Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB1 plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyReviewSCOPUS10.3892/etm.2011.310